A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses

Trial Profile

A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Ciprofloxacin (Primary) ; Ciprofloxacin (Primary) ; Antibacterials
  • Indications Bacterial infections; Paediatric infections
  • Focus Adverse reactions
  • Acronyms QUIP
  • Sponsors Bayer
  • Most Recent Events

    • 18 Apr 2009 Actual patient number (1029) added as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Actual initiation date changed from Apr 2000 to Oct 1999 as reported by ClinicalTrials.gov.
    • 16 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top